78 related articles for article (PubMed ID: 26391308)
1. A convenient method for the preparation of radioiodinated meta-iodobenzylguanidine at a no-carrier-added level.
Wang G; Chen Z; Wu E; Wang Y; Huang H
J Labelled Comp Radiopharm; 2015; 58(11-12):442-4. PubMed ID: 26391308
[TBL] [Abstract][Full Text] [Related]
2. A convenient solution-phase method for the preparation of meta-iodobenzylguanidine in high effective specific activity.
Donovan AC; Valliant JF
Nucl Med Biol; 2008 Oct; 35(7):741-6. PubMed ID: 18848658
[TBL] [Abstract][Full Text] [Related]
3. No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue.
Vaidyanathan G; Affleck DJ; Zalutsky MR
Appl Radiat Isot; 2005 Mar; 62(3):435-40. PubMed ID: 15607920
[TBL] [Abstract][Full Text] [Related]
4. [A simple and rapid routine preparation of no-carrier added meta-I-123- and I-131-iodobenzylguanidine (I-123-MIBG and I-131-MIBG) for clinical nuclear medicine applications].
Samnick S; Kirsch CM
Nuklearmedizin; 1999; 38(7):292-6. PubMed ID: 10599069
[TBL] [Abstract][Full Text] [Related]
5. An efficient batch preparation of high specific activity.
Amartey JK; Al-Jammaz I; Lambrecht RM
Appl Radiat Isot; 2001 May; 54(5):711-4. PubMed ID: 11258518
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of radioiodination of meta-iodobenzylguanidine (MIBG) catalysed by in situ generated Cu(I) and directly added Cu(II).
Prabhakar G; Mehra KS; Ramamoorthy N; Chattopadhyay S; Oommen R; Narasimhan S; Nair NA; Gunasekaran S
Appl Radiat Isot; 1999 Jun; 50(6):1011-4. PubMed ID: 10355103
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of ring- and side-chain-substituted m-iodobenzylguanidine analogues.
Vaidyanathan G; Shankar S; Zalutsky MR
Bioconjug Chem; 2001; 12(5):786-97. PubMed ID: 11562197
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a fast and high yield method for routine production of [(131) I]MIBG and investigation of its radiochemical stability for diagnosis and treatment uses.
Davarpanah MR; Attar Nosrati S; Khoshhosn HA; Fazlali M; Kazemi Boudani M
J Labelled Comp Radiopharm; 2013 Nov; 56(13):686-8. PubMed ID: 25196031
[TBL] [Abstract][Full Text] [Related]
9. A kit method for the high level synthesis of [211At]MABG.
Vaidyanathan G; Affleck DJ; Alston KL; Zhao XG; Hens M; Hunter DH; Babich J; Zalutsky MR
Bioorg Med Chem; 2007 May; 15(10):3430-6. PubMed ID: 17387017
[TBL] [Abstract][Full Text] [Related]
10. A hybrid solid-fluorous phase radioiodination and purification platform.
Dzandzi JP; Vera DR; Valliant JF
J Labelled Comp Radiopharm; 2014 Jul; 57(9):551-7. PubMed ID: 25069901
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
12. Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine.
Vaidyanathan G; Zalutsky MR; DeGrado TR
Bioconjug Chem; 1998; 9(6):758-64. PubMed ID: 9815170
[TBL] [Abstract][Full Text] [Related]
13. No-carrier-added synthesis of meta-[131I]iodobenzylguanidine.
Vaidyanathan G; Zalutsky MR
Appl Radiat Isot; 1993 Mar; 44(3):621-8. PubMed ID: 8472027
[TBL] [Abstract][Full Text] [Related]
14. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
15. A rapid and efficient preparation of [123I]radiopharmaceuticals using a small HPLC (Rocket) column.
Katsifis A; Papazian V; Jackson T; Loc'h C
Appl Radiat Isot; 2006 Jan; 64(1):27-31. PubMed ID: 16129607
[TBL] [Abstract][Full Text] [Related]
16. Meta-iodobenzylguanidine and analogues: chemistry and biology.
Vaidyanathan G
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):351-68. PubMed ID: 19088690
[TBL] [Abstract][Full Text] [Related]
17. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
Fullerton NE; Boyd M; Ross SC; Pimlott SL; Babich J; Kirk D; Zalutsky MR; Mairs RJ
Med Chem; 2005 Nov; 1(6):611-8. PubMed ID: 16787344
[TBL] [Abstract][Full Text] [Related]
18. The vial kit formulation for preparation of no-carrier-added
Chen Z; Wang G; Xie M; Huang H; Wu E; Wang Y
J Labelled Comp Radiopharm; 2018 Feb; 61(2):107-111. PubMed ID: 28833455
[TBL] [Abstract][Full Text] [Related]
19. Meta-iodobenzylguanidine derivatives containing a second guanidine moiety.
Vaidyanathan G; Shankar S; Affleck DJ; Alston K; Norman J; Welsh P; LeGrand H; Zalutsky MR
Bioorg Med Chem; 2004 Apr; 12(7):1649-56. PubMed ID: 15028258
[TBL] [Abstract][Full Text] [Related]
20. Effect of specific activity on cardiac uptake of iodine-123-MIBG.
Farahati J; Bier D; Scheubeck M; Lassmann M; Schelper LF; Grelle I; Hanscheid H; Biko J; Graefe KH; Reiners C
J Nucl Med; 1997 Mar; 38(3):447-51. PubMed ID: 9074536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
